
    
      PRIMARY OBJECTIVES:

      I. To evaluate the safety and anti-cancer activities in patients with relapsed or refractory
      small cell lung cancer (SCLC) who have failed 1 or 2 lines of chemotherapy.

      OUTLINE:

      Patients receive CPI-613 intravenously (IV) over 2 hours on days 1 and 4 of weeks 1-3.
      Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 2 months.
    
  